Robust methylation-based classification of brain tumors using nanopore sequencing
Abstract DNA methylation-based classification of cancer provides a comprehensive molecular approach to diagnose tumors. In fact, DNA methylation profiling of human brain tumors already profoundly impacts clinical neuro-oncology. However, current implementations using hybridization microarrays are time-consuming and costly. We recently reported on shallow nanopore whole-genome sequencing for rapid and cost-effective generation of genome-wide 5-methylcytosine profiles as input to supervised classification using random forests complemented by a medium-resolution copy number profile derived from the same raw data. Here, we demonstrate that this approach allows to discriminate a wide spectrum of primary brain tumors using public reference data of 82 distinct tumor entities. We developed a pseudo-probability score as a confidence score for interpretation in a clinical context. Using bootstrap sampling in a discovery cohort of N = 56 cases, we find that a minimum set of 1,000 random CpG features is sufficient for high-confidence classification by ad hoc random forests for most cases and demonstrate robustness across laboratories with matching results in 13/13 cases. When applying the confidence score threshold to an independent validation series (N = 111), the method demonstrated 100% specificity for the remaining 93 cases. In a prospective benchmarking (N = 15), median time to results was 21.1 hours. In conclusion, nanopore sequencing allows robust and rapid methylation-based classification across the full spectrum of brain tumors. The integrated confidence score facilitates possible clinical implementation, while requiring further prospective evaluation..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
bioRxiv.org - (2021) vom: 10. März Zur Gesamtaufnahme - year:2021 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kuschel, Luis P. [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
doi: |
10.1101/2021.03.06.21252627 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XBI020103743 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XBI020103743 | ||
003 | DE-627 | ||
005 | 20230429085035.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210310s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1101/2021.03.06.21252627 |2 doi | |
035 | |a (DE-627)XBI020103743 | ||
035 | |a (DE-599)biorXiv10.1101/2021.03.06.21252627 | ||
035 | |a (biorXiv)10.1101/2021.03.06.21252627 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | |a 570 |q DE-84 | |
100 | 1 | |a Kuschel, Luis P. |e verfasserin |4 aut | |
245 | 1 | 0 | |a Robust methylation-based classification of brain tumors using nanopore sequencing |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract DNA methylation-based classification of cancer provides a comprehensive molecular approach to diagnose tumors. In fact, DNA methylation profiling of human brain tumors already profoundly impacts clinical neuro-oncology. However, current implementations using hybridization microarrays are time-consuming and costly. We recently reported on shallow nanopore whole-genome sequencing for rapid and cost-effective generation of genome-wide 5-methylcytosine profiles as input to supervised classification using random forests complemented by a medium-resolution copy number profile derived from the same raw data. Here, we demonstrate that this approach allows to discriminate a wide spectrum of primary brain tumors using public reference data of 82 distinct tumor entities. We developed a pseudo-probability score as a confidence score for interpretation in a clinical context. Using bootstrap sampling in a discovery cohort of N = 56 cases, we find that a minimum set of 1,000 random CpG features is sufficient for high-confidence classification by ad hoc random forests for most cases and demonstrate robustness across laboratories with matching results in 13/13 cases. When applying the confidence score threshold to an independent validation series (N = 111), the method demonstrated 100% specificity for the remaining 93 cases. In a prospective benchmarking (N = 15), median time to results was 21.1 hours. In conclusion, nanopore sequencing allows robust and rapid methylation-based classification across the full spectrum of brain tumors. The integrated confidence score facilitates possible clinical implementation, while requiring further prospective evaluation. | ||
700 | 1 | |a Hench, Jürgen |e verfasserin |4 aut | |
700 | 1 | |a Frank, Stephan |e verfasserin |4 aut | |
700 | 1 | |a Hench, Ivana Bratic |e verfasserin |4 aut | |
700 | 1 | |a Girard, Elodie |e verfasserin |4 aut | |
700 | 1 | |a Blanluet, Maud |e verfasserin |4 aut | |
700 | 1 | |a Masliah-Planchon, Julien |e verfasserin |4 aut | |
700 | 1 | |a Misch, Martin |e verfasserin |4 aut | |
700 | 1 | |a Onken, Julia |e verfasserin |4 aut | |
700 | 1 | |a Czabanka, Marcus |e verfasserin |4 aut | |
700 | 1 | |a Karau, Philipp |e verfasserin |4 aut | |
700 | 1 | |a Ishaque, Naveed |e verfasserin |4 aut | |
700 | 1 | |a Hain, Elisabeth G. |e verfasserin |4 aut | |
700 | 1 | |a Heppner, Frank |e verfasserin |4 aut | |
700 | 1 | |a Idbaih, Ahmed |e verfasserin |4 aut | |
700 | 1 | |a Behr, Nikolaus |e verfasserin |4 aut | |
700 | 1 | |a Harms, Christoph |e verfasserin |4 aut | |
700 | 1 | |a Capper, David |e verfasserin |4 aut | |
700 | 1 | |a Euskirchen, Philipp |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 10. März |
773 | 1 | 8 | |g year:2021 |g day:10 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.03.06.21252627 |z kostenfrei |3 Volltext |
912 | |a GBV_XBI | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2021 |b 10 |c 03 | ||
953 | |2 045F |a 570 |